FILE PHOTO: An ampule of Gilead Sciences COVID-19 antiviral remdesivir is pictured during a news conference at the University Hospital Eppendorf (UKE) in Hamburg, Germany, April 8, 2020, as the spread of coronavirus disease (COVID-19) continues. Ulrich Perrey/Pool via REUTERS
LONDON (Reuters) - When it comes to trials of any drug, size matters, potentially giving the World Health Organization's (WHO) gloomy verdict on Gilead Sciences' COVID-19 treatment remdesivir an edge over the company's more positive data, leading scientists say.
Gilead's drug - an antiviral originally developed to treat Ebola - showed no benefit on survival rates, according to the results of the world's largest randomized clinical trial of potential COVID-19 drugs run by the WHO.
Win a prize this Mother's Day by subscribing to our annual plan now! T&C applies.
